Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Sedlmayer, F; Höltl, W; Kozak, W; Hawliczek, R; Gebhart, F; Gerber, E; Joos, H; Albrecht, W; Pummer, K; Kogelnik, HD; Australian Uro-Oncology Group (AUO).
Radiotherapy of testicular intraepithelial neoplasia (TIN): a novel treatment regimen for a rare disease.
Int J Radiat Oncol Biol Phys. 2001; 50(4):909-913
Doi: 10.1016/S0360-3016(01)01483-3
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Pummer Karl
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- PURPOSE: Testicular intraepithelial neoplasia (TIN) is a consistent precursor of most invasive germ cell tumors, currently treated by radiotherapy with 20 Gy, which destroys TIN but preserves Leydig cells. Nevertheless, analysis has shown dose-dependent dysfunction even with low therapeutic doses of 20 Gy in some cases. Therefore, we tested a dose reduction regimen by delivering smaller fractional doses to enhance the tolerance of Leydig cells. METHODS AND MATERIALS: Between 1993 and 1999, 9 patients were treated for TIN in a prospective multicenter trial. A total dose of 13 Gy was administered in 10 fractions of 1.3 Gy. Hormonal levels of follicle-stimulating hormone, luteinizing hormone, and testosterone were assayed serially. RESULTS: During a median follow-up time of 36 months, no patient showed evidence of local disease. A first postradiation biopsy was obtained 3-12 months after radiotherapy; 5 patients underwent a second biopsy 2-3 years after treatment. All biopsies showed a Sertoli cell-only pattern. Follicle-stimulating hormone levels continued to increase 1 year after radiotherapy, signaling eradicated spermiogenesis. Luteinizing hormone and testosterone remained within the normal range 2 years after radiotherapy. CONCLUSIONS: In the treatment of TIN, there seems to be a dose reduction potential to 13 Gy by lowering single fractional doses, which enhances the therapeutic ratio in favor of the Leydig cells.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Biological Markers - blood
- Carcinoma in Situ - blood
- Dose Fractionation - blood
- Follicle Stimulating Hormone - blood
- Follow-Up Studies - blood
- Humans - blood
- Leydig Cells - radiation effects
- Luteinizing Hormone - blood
- Male - blood
- Radiation Tolerance - blood
- Spermatogonia - radiation effects
- Testicular Neoplasms - blood
- Testosterone - blood
- Find related publications in this database (Keywords)
- radiotherapy
- testicular intraepithelial neoplasia
- TIN
- germ cells
- Leydig cells